Form 8-K ARVINAS, INC. For: Apr 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Arvinas Inc. (ARVN) Enters License and Asset Agreement with Novartis
April 11, 2024 7:11 AM EDTOn April 10, 2024, Arvinas Inc. (NASDAQ: ARVN), entered into a transaction (the Transaction), including both a license agreement (the License Agreement) and an asset purchase agreement (the Asset Agreement), with Novartis Pharma AG (Novartis). Pursuant to the License Agreement, the Company will grant to Novartis an exclusive worldwide license for the development, manufacture and commercialization of ARV-766, the Companys second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer. Pursuant to the Asset Agreement, the... More
